Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacey J Baker

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|February 20, 2025
A <i>Drosophila</i> model for Costello Syndrome caused by Ras mutation K117RPrashath Karunaraj, Emily Cao, Harnoor Singh, et al.
Nature Communications|July 7, 2022
TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesisYuhan Xia, Kazuki Inoue, Yong Du, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceKiranmai Gumireddy, Stacey J Baker, Stephen C Cosenza, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell developmentStacey J Baker, Avi Ma'ayan, Yen K Lieu, et al.
Molecular Cell|July 4, 2020
A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding AgentStacey J Baker, Stephen C Cosenza, Saikrishna Athuluri-Divakar, et al.
Cancer Cell|March 16, 2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentKiranmai Gumireddy, M V Ramana Reddy, Stephen C Cosenza, et al.
Oncotarget|February 1, 2019
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemiaAmol Padgaonkar, Olga Rechkoblit, Rodgrigo Vasquez-Del Carpio, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Nature Communications|August 4, 2021
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant diseaseKatsutoshi Sato, Amol A Padgaonkar, Stacey J Baker, et al.
Journal of Medicinal Chemistry|January 15, 2014
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)M V Ramana Reddy, Balireddy Akula, Stephen C Cosenza, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|February 20, 2025
A <i>Drosophila</i> model for Costello Syndrome caused by Ras mutation K117RPrashath Karunaraj, Emily Cao, Harnoor Singh, et al.
Nature Communications|July 7, 2022
TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesisYuhan Xia, Kazuki Inoue, Yong Du, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceKiranmai Gumireddy, Stacey J Baker, Stephen C Cosenza, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell developmentStacey J Baker, Avi Ma'ayan, Yen K Lieu, et al.
Molecular Cell|July 4, 2020
A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding AgentStacey J Baker, Stephen C Cosenza, Saikrishna Athuluri-Divakar, et al.
Cancer Cell|March 16, 2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentKiranmai Gumireddy, M V Ramana Reddy, Stephen C Cosenza, et al.
Oncotarget|February 1, 2019
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemiaAmol Padgaonkar, Olga Rechkoblit, Rodgrigo Vasquez-Del Carpio, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Nature Communications|August 4, 2021
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant diseaseKatsutoshi Sato, Amol A Padgaonkar, Stacey J Baker, et al.
Journal of Medicinal Chemistry|January 15, 2014
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)M V Ramana Reddy, Balireddy Akula, Stephen C Cosenza, et al.
Pageof 3